[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019091450A1 - 一种苯并呋喃衍生物的制备方法 - Google Patents

一种苯并呋喃衍生物的制备方法 Download PDF

Info

Publication number
WO2019091450A1
WO2019091450A1 PCT/CN2018/114798 CN2018114798W WO2019091450A1 WO 2019091450 A1 WO2019091450 A1 WO 2019091450A1 CN 2018114798 W CN2018114798 W CN 2018114798W WO 2019091450 A1 WO2019091450 A1 WO 2019091450A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
formula
preparation
alkyl
Prior art date
Application number
PCT/CN2018/114798
Other languages
English (en)
French (fr)
Inventor
陆伟栋
徐超
张浩宇
邵启云
冯君
贺峰
Original Assignee
江苏恒瑞医药股份有限公司
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司, 上海恒瑞医药有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to EP18875981.5A priority Critical patent/EP3708567A4/en
Priority to CN201880059239.2A priority patent/CN111094279B/zh
Priority to MX2020004869A priority patent/MX2020004869A/es
Priority to JP2020525952A priority patent/JP7295105B6/ja
Priority to US16/762,795 priority patent/US11390614B2/en
Priority to AU2018363467A priority patent/AU2018363467B2/en
Priority to RU2020118301A priority patent/RU2777624C2/ru
Publication of WO2019091450A1 publication Critical patent/WO2019091450A1/zh
Priority to JP2023094525A priority patent/JP7526856B2/ja
Priority to AU2023278061A priority patent/AU2023278061A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for the preparation of a benzofuran derivative.
  • Lymphoma is a malignant tumor originating from the lymphoid hematopoietic system. It is classified into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) according to the tumor cells.
  • NHL non-Hodgkin's lymphoma
  • HL Hodgkin's lymphoma
  • NHL mainly pathologically. It is a lymphocyte, tissue cell or reticular cell with different degrees of differentiation.
  • lymphocyte origins it can be divided into three different clinical types. It is a B cell, T cell and natural killer (NK) cell lymphoma, in which the main function of B cell is to secrete various antibodies to help the body resist various external invasions.
  • NK natural killer
  • the histone methyltransferase encoded by the EZH2 gene is a catalytic component of the polycomb inhibitory complex 2 (PRC2).
  • PRC2 polycomb inhibitory complex 2
  • EZH2 levels were abnormally elevated in cancer tissues, while EZH2 was the highest in advanced cancer or poor prognosis.
  • EZH2 overexpression coincides with amplification of the EZH2 gene.
  • si/shRNA experiments have found that reducing EZH2 expression in tumor cell lines inhibits tumor cell proliferation, migration and invasion or angiogenesis, and leads to apoptosis.
  • EZH2 inhibitors have entered the stage of clinical development.
  • Tazemetostat EZ-6438 developed by Eisai for the treatment of non-Hodgkin B-cell lymphoma, which is currently in clinical phase II
  • CPI developed by Constellation.
  • -1205 is used to treat B-cell lymphoma. It is currently in the clinical stage I.
  • GSK-2816126 developed by GlaxoSmithKline is used to treat diffuse large B-cell lymphoma and follicular lymphoma. It is currently in clinical stage I.
  • the preparation of the compound Ia is also disclosed in the application, but the preparation of the above compound by the method disclosed in the application requires up to fourteen steps (e.g., Scheme1), and the route is characterized by nitration, bromination and hydrolysis of the fourth step diazonium salt.
  • steps e.g., Scheme1
  • the route is characterized by nitration, bromination and hydrolysis of the fourth step diazonium salt.
  • the two-step reaction is regioselective, and the isomers are difficult to separate and purify
  • the multi-step process requires column chromatography, which is not suitable for industrial production. Therefore, simplifying the synthesis method of the substance and shortening the corresponding reaction step still have research value.
  • the present invention provides a novel process for the preparation of a benzofuran derivative by which the step of preparing a benzofuran derivative can be significantly reduced by the process of the present invention.
  • the present invention provides a process for the preparation of a benzofuran derivative of the formula IV, characterized in that a compound of the formula VI is reacted with a compound of the formula V to give a compound of the formula IV,
  • X and Y are each independently selected from the group consisting of fluorine, chlorine, bromine, iodine, -OS(O) 2 alkyl, and -OS(O) 2 aryl, preferably iodine or bromine;
  • R 1 , R 2 and R 3 are each the same or different and are each independently selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, an alkoxy group, a halogenated alkoxy group, an amino group, a nitro group, a hydroxyl group, a cyano group, a cycloalkyl group.
  • E is selected from the group consisting of hydrogen atom, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 4 , -C ( O) R 4 , -C(O)OR 4 , -OS(O) 2 alkyl, and -OS(O) 2 aryl, -S(O) m R 4 , -S(O) m NR 5 R 6 and -(CH 2 )xR a , wherein the alkyl, haloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally selected from the group consisting of alkyl, haloalkyl, halo, amino, nitro Substituted with one or more substituents of cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl
  • R a is selected from the group consisting of halogen, cycloalkyl, heterocyclic and -NR 5 R 6 , wherein said cycloalkyl and heterocyclic groups are each independently optionally selected from the group consisting of alkyl, haloalkyl, halogen, amino, and nitrate Substituted by one or more substituents of the group, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 4 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, an alkoxy group, a hydroxyalkyl group, a hydroxyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
  • R 5 and R 6 are the same or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyalkyl group, a hydroxyl group, an amino group, a carboxylate group, a cycloalkyl group, a heterocyclic group, an aryl group, and a hetero group.
  • alkyl group wherein said alkyl group, amino group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are each independently optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, carboxylate, nitro Substituting one or more substituents of a cyano group, an alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
  • M is selected from a carboxyl group, a hydrogen, a silane group, preferably hydrogen;
  • n 0, 1 or 2;
  • x 0, 1, 2 or 3.
  • the process for the preparation of a compound of formula IV provided by the present invention is carried out by reacting a compound of formula VI with a compound of formula V as a starting material under the action of at least one metal catalyst and/or at least one basic substance.
  • the present invention provides a process for the preparation of a compound of formula IV selected from the group consisting of metal palladium catalysts, metal zinc catalysts, metal copper catalysts, metal nickel catalysts, preferably metal copper catalysts, more preferably monovalent metal copper catalysts.
  • metal catalysts described in the present invention include CuI, CuBr, Pd 2 (dba) 3 , Pd(dba) 2, Pd(PPh 3 ) 4 , (Ph 3 P) 2 PdCl 2 , Pd ( OAc) 2 , Pd(tfa) 2 , Pd(Piv) 2 , Pd(OTf) 2 , CuCl, Cu 2 O, ZnCl 2 , preferably CuI.
  • the method for preparing a compound of the formula IV provided by the present invention is characterized in that the basic substance is selected from the group consisting of KHCO 3 , NaHCO 3 , Na 2 CO 3 , Ba(OH) 2 , K 3 PO 4 , Cs 2 CO 3 , K 2 CO 3 , KF, CsF, KCN, NaCN, NaOH, KOH, Et 3 N, DIPEA, DABCO, NaOMe, NaOEt, t BuOK, t BuONa, NaH, DBU, TMG, LHMDS, NaHMDS, n-BuLi, sodium t-amylate Diethylamine, dicyclohexylamine, preferably t BuOK, t BuONa.
  • the basic substance is selected from the group consisting of KHCO 3 , NaHCO 3 , Na 2 CO 3 , Ba(OH) 2 , K 3 PO 4 , Cs 2 CO 3 , K 2 CO 3 , KF, CsF, KCN, Na
  • the reaction solvent for the process for preparing the compound of the formula IV provided by the present invention is selected from the group consisting of ethyl acetate, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, and One or more of toluene, dimethyl sulfoxide, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, isopropanol, propanol, ethanol, methanol, and water.
  • the process for the preparation of the compound of formula IV provided by the present invention is characterized in that the reaction is carried out under the protection of an inert gas selected from the group consisting of nitrogen, argon and helium, preferably argon.
  • the present invention provides a method of reacting a compound of formula VIa with a compound of formula Va to give a compound of formula IVa,
  • the present invention also provides a process for the preparation of a compound of the formula VIa, characterized in that the compound of the formula VIIa is produced by the bromination reagent and at least one acid to produce a compound represented by VIa.
  • the method for preparing a compound of the formula VIa provided by the present invention is characterized in that the brominated reagent is selected from the group consisting of HBr, Br 2 , NBS, DBDMH, HOBr, AcOBr, CF 3 COOBr, NH 4 Br, TBBDA, PBBS, tribromo Isocyanourea, preferably NBS, DBDMH.
  • the invention provides a method for preparing a compound of the formula VIa, wherein the acid is selected from the group consisting of AlCl 3 , SbCl 5 , FeCl 3 , FeBr 3 , SnCl 4 , TiCl 4 , ZnCl 2 , BF 3 , acetic acid, sulfuric acid, hydrochloric acid and trifluoroethylene.
  • Acetic acid preferably sulfuric acid, trifluoroacetic acid.
  • the process for the preparation of a compound of formula IVa provided herein provides, optionally, a process for the preparation of a compound of formula VIa provided herein.
  • the process for the preparation of the compound of formula IVa provided by the present invention is characterized in that the reaction is carried out under the protection of an inert gas selected from the group consisting of nitrogen, argon and helium, preferably argon.
  • the present invention also provides a process for the preparation of a compound of the formula VIIa, characterized in that the compound of the formula VIIIa is selected from one or more selected from the group consisting of Pd 2 (dba) 3 , Pd (dba) 2 , Pd (OAc) 2 , Pd (tfa) 2 , Pd(Piv) 2 , Pd(OTf) 2 , Pd(PPh 3 ) 4 , PdCl 2 , Pd(PPh 3 ) 2 Cl 2 , Pd(dppf)Cl 2 palladium catalyst and one or more An iodine reagent selected from the group consisting of NIS, I(Py) 2 BF 4 , IOAC, KI, KIO 3 , NaI, IBr gives a compound of the formula VIIa, and the palladium catalyst is preferably Pd(OAc) 2 , the iodine The generation reagent is preferably NIS.
  • the process for the preparation of a compound of the formula VIIa according to the invention is characterized in that the reaction is carried out under the protection of an inert gas selected from the group consisting of nitrogen, argon and helium, preferably argon.
  • the catalyst is used in an amount of from 0.01% to 20%, preferably from 0.1% to 10%, most preferably from 1% to 5%, based on the compound of the formula VIIIa.
  • the reaction solvent is not specifically limited, and the exemplary solvent may be selected from N,N-dimethylformamide, N,N-dimethylacetamide, dichloromethane. , ethanol, methanol, dimethyl sulfoxide, acetonitrile, acetone, chloroform.
  • the present invention provides a process for the preparation of a compound of formula VIa, which optionally comprises the step of preparing a compound of formula VIIa provided by the present invention.
  • the present invention also provides a process for the preparation of the compound of the formula IIIa, characterized in that the compound of the formula VIa is reacted with tetrahydro-2H-pyran-4-amine to give a compound of the formula IIIa,
  • the preparation method of the compound of the formula IIIa provided by the present invention can be carried out under the action of DPE-Phos, sodium t-butoxide and a palladium catalyst.
  • the preparation method of the compound of the formula IIIa provided by the present invention optionally comprises a method of preparing the compound of the formula IVa, the compound of the formula VIa and the compound of the formula VIIa provided by the present invention. .
  • the present invention also provides a process for the preparation of a compound of the formula IIa, characterized in that the compound of the formula IIIa is N-ethylated to give a compound of the formula IIa.
  • the preparation method of the compound of the formula IIa provided by the present invention optionally comprises a method of preparing the compound of the formula IIIa, the compound of the formula IVa, the compound of the formula VIa and the compound of the formula VIIa provided by the present invention.
  • the invention also provides a process for the preparation of a compound of formula Ia, characterized in that it comprises a compound of formula IIa and 3-(aminomethyl)-4,6-lutidine-2(1H)-one salt
  • the process for the preparation of a compound of formula Ia which is provided by the invention, optionally comprises a process for the preparation of a compound of formula IIIa provided by the invention.
  • the process for the preparation of a compound of formula Ia which is provided by the invention, optionally comprises a process for the preparation of a compound of formula IVa provided by the invention.
  • the invention also provides a compound of formula IV,
  • R 1 , R 2 and R 3 are as defined above.
  • the invention also provides a compound of formula VI,
  • the invention also provides a compound of formula VIa:
  • the invention also provides a compound of formula IVa:
  • the invention also provides a compound of formula IIIa:
  • the method for producing a compound of the formula IIa from the compound IIIa represented by the formula provided by the present invention can be specifically referred to the similar preparation method disclosed in Example 1 of PCT application WO2017084494A.
  • the present invention provides a process for the preparation of a compound of the formula Ia to a compound of the formula Ia, in particular a process for the preparation of an amide as disclosed in PCT Application Nos. WO2017084494A, WO2012142513, WO2013039988, WO2015-141616, WO2011140325.
  • the compound of the formula Ia provided by the present invention can be specifically prepared by the following route, and the reaction conditions can be selected from the conditions in the specific steps described above.
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
  • the alkyl group of the atom is a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 - dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -methylhexyl, 3-methylhexyl, 4-methylhexyl,
  • lower alkyl groups having from 1 to 6 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
  • the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups independently selected from the group consisting of an alkane Base, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, naphthenic An oxy group, a heterocycloalkoxy group, a cycloalkylthio group, a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
  • an alkane Base alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, hetero
  • alkylene means that one hydrogen atom of the alkyl group is further substituted, for example, "methylene” refers to -CH 2 -, "ethylene” refers to -(CH 2 ) 2 -, "propylene” Refers to -(CH 2 ) 3 -, "butylene” means -(CH 2 ) 4 - and the like.
  • alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or -butenyl and the like.
  • the alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio group.
  • spirocycloalkyl refers to a polycyclic group that shares a carbon atom (referred to as a spiro atom) between 5 to 20 members of a single ring, which may contain one or more double bonds, but none of the rings have a fully conjugated ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
  • the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the rings.
  • spirocycloalkyl groups include:
  • fused cycloalkyl refers to 5 to 20 members, and each ring in the system shares an all-carbon polycyclic group of an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
  • fused cycloalkyl groups include:
  • bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two carbon atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have complete Conjugate ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring.
  • bridged cycloalkyl groups include:
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Base, benzocycloheptyl and the like.
  • the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 6 carbon atoms. One carbon atom.
  • Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
  • a polycycloalkyl group includes a spiro ring, a fused ring, and a cycloalkyl group.
  • spiroheterocyclyl refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between 5 to 20 members of a single ring, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O). ) m (where m is an integer 0 to 2) heteroatoms, and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
  • the spiroheterocyclyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspirocyclic group according to the number of shared spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
  • Non-limiting examples of spiroheterocyclyl groups include:
  • fused heterocyclyl refers to 5 to 20 members, and each ring in the system shares an adjacent pair of atomic polycyclic heterocyclic groups with other rings in the system, and one or more rings may contain one or more Double bond, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining rings
  • the atom is carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
  • fused heterocyclic groups include:
  • bridge heterocyclyl refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have a total A ⁇ -electron system of a yoke in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), the remaining ring atoms being carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
  • bridge heterocyclic groups include:
  • the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples of which include:
  • the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more ring atoms are selected from nitrogen, oxygen or S(O).
  • a hetero atom of m (where m is an integer of 0 to 2), but excluding the ring moiety of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • ring atoms Preferably comprising from 3 to 12 ring atoms, wherein from 1 to 4 are heteroatoms; most preferably from 3 to 8 ring atoms, wherein from 1 to 3 are heteroatoms; most preferably from 3 to 6 ring atoms, wherein from 1 to 2 It is a hetero atom.
  • monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine.
  • Piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc. preferably piperidinyl, pyrrolidinyl, pyranyl, morpholinyl or Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
  • aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (ie, a ring that shares a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably 6 to 10 members, such as benzene. Base and naphthyl. More preferred is phenyl.
  • the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples of which include:
  • the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle An alkylthio group, a carboxyl group or a carboxylate group.
  • heteroaryl refers to a heteroaromatic system containing from 1 to 4 heteroatoms, from 5 to 14 ring atoms, wherein the heteroatoms are selected from the group consisting of oxygen, sulfur and nitrogen.
  • the heteroaryl group is preferably 5 to 10 members, and has 1 to 3 hetero atoms; more preferably 5 or 6 members, and 1 to 2 hetero atoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridyl Azolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, tetrazolyl, thienyl, pyrazolyl or pyrimidinyl, thiazolyl More selective pyrazolyl or thiazolyl.
  • the heteroaryl ring may be fused to an a
  • the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
  • alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
  • alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
  • haloalkyl refers to an alkyl group substituted by one or more halogens, wherein alkyl is as defined above.
  • haloalkoxy refers to an alkoxy group substituted by one or more halogens, wherein alkoxy is as defined above.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
  • hydroxy refers to an -OH group.
  • halogen means fluoro, chloro, bromo or iodo.
  • amino means -NH 2.
  • cyano refers to -CN.
  • nitro refers to -NO 2 .
  • isocyanato refers to -NCO.
  • carboxylate group refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl, cycloalkyl are as defined above.
  • heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group.
  • Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS).
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • the NMR was measured by a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane ( TMS), chemical shifts are given in units of 10 -6 (ppm).
  • the measurement of the MS was carried out using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
  • ESI FINNIGAN LCQAd
  • the HPLC was measured using a WATER e2695-2489 high performance liquid chromatograph.
  • the known starting materials of the present invention can be synthesized by or according to methods known in the art, or can be purchased from companies such as BEPHARM.
  • VIIa (27.6 g, 83 mmol) was dissolved in 138 mL of concentrated sulfuric acid (5 mL / g), cooled to 0-5 ° C, N-bromosuccinimide (19.6 g, 110 mmol) was dissolved in trifluoroacetic acid, slowly drip Add the above N-bromosuccinimide trifluoroacetic acid solution to the reaction solution, add it, naturally increase to room temperature, react for a period of time, then continue to rise 40 ° C, then add N-bromosuccinamide The amine trifluoroacetic acid solution (14.2 g, 80 mmol) was quenched and the reaction was stopped after the detection of VIIa ⁇ 2%.
  • the third step 6-bromo-5-ethyl-2-(piperidin-1-ylmethyl)benzofuran-4-carboxylic acid
  • Step 5 5-Ethyl-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-(piperidin-1-ylmethyl)benzofuran-4-carboxylic acid
  • the raw material IIIa 120 mg, 0.31 mmol was placed in a 25 mL three-necked flask, 3 mL of DCM was added, and acetaldehyde (69 mg, 1.55 mmol) and acetic acid (94 mg, 1.55 mmol) were added in an ice bath, and the reaction was stirred for 0.5 hour under ice bath.
  • Sodium triacetoxyborohydride 198 mg, 0.93 mmol was added portionwise, and the mixture was warmed to room temperature, and the reaction was stirred until the thin layer was traced until the starting point IIIa disappeared, and the reaction was terminated.
  • Step 6 N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-ethyl-6-(ethyl (tetrahydro) -2H-pyran-4-yl)amino)-2-(piperidin-1-ylmethyl)benzofuran-4-carboxamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种苯并呋喃衍生物的制备方法。具体而言，提供一种苯并呋喃衍生物的制备方法，根据提供的方法，可以有效的缩短现有技术中合成苯并呋喃类物质所需的反应步骤。

Description

一种苯并呋喃衍生物的制备方法
本申请要求申请日为2017年11月10日的中国专利申请CN201711104888.3的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明涉及一种苯并呋喃衍生物的制备方法。
背景技术
淋巴瘤是起源于淋巴造血系统的恶性肿瘤，根据瘤细胞分为非霍奇金淋巴瘤(NHL)和霍奇金淋巴瘤(HL)两类，在亚洲，90％患者为NHL，病理上主要是分化程度不同的淋巴细胞、组织细胞或网状细胞，根据NHL的自然病程，可以归为三大临床类型，即高度侵袭性、侵袭性和惰性淋巴瘤；根据不同的淋巴细胞起源，可以分为B细胞、T细胞和自然杀伤(natural killer，NK)细胞淋巴瘤，其中B细胞的主要职能是分泌各种抗体帮助人体抵御各种外来的侵入。
EZH2基因编码的组蛋白甲基转移酶是多梳蛋白抑制性复合体2(PRC2)的催化组分。与正常组织相比，EZH2水平在癌组织异常升高，而在癌症晚期或不良预后中，EZH2的表达水平最高。在一些癌症类型中，EZH2表达过剩与EZH2基因的扩增同时发生。大量si/shRNA实验研究发现在肿瘤细胞系中减少EZH2表达，可抑制肿瘤细胞的增殖，迁移和侵袭或血管生成，并导致细胞凋亡。
目前已有进入临床开发阶段的EZH2抑制剂，以下简要列举，卫材开发的Tazemetostat(EPZ-6438)用于治疗非霍奇金B细胞淋巴瘤，目前处于临床Ⅱ期阶段，Constellation公司开发的CPI-1205用于治疗B细胞淋巴瘤，目前处于临床Ⅰ期阶段，葛兰素史克公司开发的GSK-2816126用于治疗弥漫大B细胞淋巴瘤、滤泡性淋巴瘤，目前处于临床Ⅰ期阶段
Figure PCTCN2018114798-appb-000001
PCT申请WO2017084494A中提供了一种EZH2抑制剂，结构如下所示：
Figure PCTCN2018114798-appb-000002
该申请中同时公开了化合物Ⅰa的制备方法，但是通过该申请中公开的方法制备上述化合物需要长达十四步骤(如Scheme1)，且该路线中硝化、溴化和第四步重氮盐水解有安全隐患；两步反应有区域选择性，异构体不易分离纯化；制备过程中多步需要柱层析的操作，不适合工业化生产。因此简化该物质的合成方法，缩短相应的反应步骤，仍然具有研究的价值，
Figure PCTCN2018114798-appb-000003
发明内容
本法明提供一种苯并呋喃衍生物的新的制备方法，通过本发明提供的方法，可以显著减少制备苯并呋喃衍生物的步骤。
本发明提供一种式Ⅳ所示的苯并呋喃衍生物的制备方法，其特征在于式Ⅵ所示化合物与式Ⅴ所示化合物发生反应得到式Ⅳ所示化合物，
Figure PCTCN2018114798-appb-000004
其中，X、Y各自独立的选自氟、氯、溴、碘，-OS(O) 2烷基、和-OS(O) 2芳基，优选碘、溴；
R 1、R 2、R 3各自相同或不同，且各自独立选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、羟基、氰基、环烷基、杂环基、芳基、杂芳基、-OR 4、-C(O)R 4、-C(O)OR 4、-OS(O) 2烷基、和-OS(O) 2芳基、-S(O) mR 4、-S(O) mNR 5R 6和-(CH 2)xR a，其中所述的烷基、卤代烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
E选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、-OR 4、-C(O)R 4、-C(O)OR 4、-OS(O) 2烷基、和-OS(O) 2芳基、-S(O) mR 4、-S(O) mNR 5R 6和-(CH 2)xR a，其中所述的烷基、卤代烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
R a选自卤素、环烷基、杂环基和-NR 5R 6，其中所述的环烷基和杂环基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
R 4选自氢原子、烷基、卤代烷基、烷氧基、羟烷基、羟基、氨基、环烷基、杂环基、芳基和杂芳基；
R 5和R 6相同或不同，且各自独立地选自氢原子、烷基、烷氧基、羟烷基、羟基、氨基、羧酸酯基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、氨基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
M选自羧基、氢、硅烷基，优选氢；
m为0、1或2；
x为0、1、2或3。
本发明提供的制备式Ⅳ所示化合物的方法，由式Ⅵ所示化合物与式Ⅴ所示化合物做为起始原料在至少一种金属催化剂和/或至少一种碱性物质的作用下反应。
本发明提供的制备式Ⅳ所示化合物的方法，所述金属催化剂选自金属钯催化剂、金属锌催化剂、金属铜催化剂、金属镍催化剂，优选金属铜催化剂，更优选一价金属铜催化剂。本发明中所述的金属催化剂的非限制性实施例包括CuI、CuBr，Pd 2(dba) 3、Pd(dba) 2，Pd(PPh 3) 4、(Ph 3P) 2PdCl 2、Pd(OAc) 2、Pd(tfa) 2、Pd(Piv) 2、Pd(OTf) 2、CuCl、Cu 2O、ZnCl 2，优选CuI。
本发明提供的制备式Ⅳ所示化合物的方法中所述碱性物质选自KHCO 3、NaHCO 3、Na 2CO 3,Ba(OH) 2、K 3PO 4、Cs 2CO 3、K 2CO 3、KF、CsF、KCN、NaCN、NaOH、KOH、Et 3N、DIPEA、DABCO、NaOMe、NaOEt、 tBuOK、 tBuONa、NaH、DBU、TMG、LHMDS、NaHMDS、n-BuLi、叔戊醇钠、二乙基胺、二环己基胺，优选 tBuOK、 tBuONa。
本发明提供的制备式Ⅳ所示化合物的方法的反应溶剂选自乙酸乙酯、二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、异丙醇、丙醇、乙醇、甲醇、水中的一种或多种。
本发明提供的制备式Ⅳ所示化合物的方法的其特征在于该反应在惰性气体保护下进行，所述惰性气体选自氮气、氩气、氦气，优选氩气。
本发明提供了一种式Ⅵa所示化合物与式Ⅴa所示化合物发生反应得到Ⅳa所示化合物的方法，
Figure PCTCN2018114798-appb-000005
本发明还提供一种式Ⅵa所示化合物的制备方法，其特征在于式Ⅶa所示化合物在溴代试剂和至少一种酸的作用下，生产Ⅵa所示化合物，
Figure PCTCN2018114798-appb-000006
本发明提供的式Ⅵa所示化合物的制备方法，其特征在于所述溴代试剂选自HBr、Br 2、NBS、DBDMH、HOBr、AcOBr、CF 3COOBr、NH 4Br、TBBDA、PBBS、三溴异氰基脲，优选NBS、DBDMH。
本发明提供的式Ⅵa所示化合物的制备方法，所述酸选自AlCl 3、SbCl 5、FeCl 3、FeBr 3、SnCl 4、TiCl 4、ZnCl 2、BF 3、醋酸、硫酸、盐酸、三氟乙酸，优选硫酸、三氟乙酸。
本发明提供的制备式Ⅳa所示化合物的方法，任选包含本发明提供的制备式Ⅵa所示化合物的方法。
本发明提供的制备式Ⅳa所示化合物的方法的其特征在于该反应在惰性气体保护下进行，所述惰性气体选自氮气、氩气、氦气，优选氩气。
本发明还提供一种式Ⅶa所示的化合物的制备方法，其特征在于式Ⅷa化合物在一种或多种选自Pd 2(dba) 3、Pd(dba) 2、Pd(OAc) 2、Pd(tfa) 2、Pd(Piv) 2、Pd(OTf) 2、Pd(PPh 3) 4、PdCl 2、Pd(PPh 3) 2Cl 2、Pd(dppf)Cl 2的钯催化剂和一种或多种选自NIS、I(Py) 2BF 4、IOAC、KI、KIO 3、NaI、IBr的碘代试剂作用下得到式Ⅶa所示化合物，所述钯催化剂优选Pd(OAc) 2，所述碘代试剂优选NIS。
Figure PCTCN2018114798-appb-000007
本发明提供的制备式Ⅶa所示化合物的方法，其特征在于该反应在惰性气体保护下进行，所述惰性气体选自氮气、氩气、氦气，优选氩气。
本发明提供的制备式Ⅶa所示化合物的方法的中，催化剂的用量为式Ⅷa化合物的0.01％-20％，优选0.1％-10％，最优选1％-5％。
本发明提供的制备式Ⅶa所示化合物的方法，反应溶剂不做具体限定，示例性的溶剂可选自N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二氯甲烷、乙醇、甲醇、二甲基亚砜、乙腈、丙酮、三氯甲烷。
本发明提供的制备式Ⅵa所示的化合物的方法，其任选包含本发明提供的制备式Ⅶa所示的化合物的步骤。
本发明还提供一种式Ⅲa所示化合的制备方法，其特征在于式Ⅵa所示化合物与四氢-2H-吡喃-4-胺反应得式Ⅲa所示化合物，
Figure PCTCN2018114798-appb-000008
本发明提供的式Ⅲa所示化合物的制备方法，可在DPE-Phos、叔丁醇钠和钯催化剂的作用下反应。
本发明提供的式Ⅲa所示化合物的制备方法任选的包含本发明提供的式Ⅳa所示化合物、式Ⅵa所示化合物、式Ⅶa所示化合物的制备方法。。
本发明还提供一种式Ⅱa所示的化合物的制备方法，其特征在于式Ⅲa所示化合物发生N-乙基化，得到Ⅱa所示化合物，
Figure PCTCN2018114798-appb-000009
本发明提供的式Ⅱa所示化合的制备方法任选的包含本发明提供的式Ⅲa所示化合物、式Ⅳa所示化合物、式Ⅵa所示化合物、式Ⅶa所示化合物的制备方法。
本发明还提供一种式Ⅰa所示的化合物的制备方法，其特征在于包含式Ⅱa所示化合物与3-(氨基甲基)-4,6-二甲基吡啶-2(1H)-酮盐酸盐反应制备得到Ⅰa的步骤，还包含权利 要求本发明提供的式Ⅱa所示化合物的制备方法，
Figure PCTCN2018114798-appb-000010
本发明提供的式Ⅰa所示的化合物的制备方法，其特征在于任选进一步包含本发明提供的制备式Ⅲa所示化合物的方法。
本发明提供的式Ⅰa所示的化合物的制备方法，其特征在于任选进一步包含本发明提供的制备式Ⅳa所示化合物的方法。
本发明还提供一种式Ⅳ所示的化合物，
Figure PCTCN2018114798-appb-000011
其中E、R 1、R 2、R 3如上所定义。
本发明还提供一种式Ⅵ所示的化合物，
Figure PCTCN2018114798-appb-000012
其中X、Y、R 1、R 2、R 3如上所定义。
本发明还提供一种式Ⅵa所示的化合物：
Figure PCTCN2018114798-appb-000013
本发明还提供一种式Ⅳa所示的化合物：
Figure PCTCN2018114798-appb-000014
本发明还提供一种式Ⅲa所示的化合物：
Figure PCTCN2018114798-appb-000015
本发明提供的由式所示化合物Ⅲa生成式Ⅱa所示的化合物的方法，具体可参考PCT申请WO2017084494A中实施例1中公开的类似的制备方法。
Figure PCTCN2018114798-appb-000016
本发明提供的由式Ⅱa所示化合物到式Ⅰa所示化合物的制备方法，具体可参考PCT申请WO2017084494A、WO2012142513、WO2013039988、WO2015-141616、WO2011140325中公开的制备酰胺的方法。
Figure PCTCN2018114798-appb-000017
本发明提供的式Ⅰa所示的化合具体可由以下路线制备，反应条件可选前述具体每一步骤中的条件
Figure PCTCN2018114798-appb-000018
发明的详细说明
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基，更优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“亚烷基”是指烷基的一个氢原子进一步被取代，例如：“亚甲基”指-CH 2-、“亚乙基”指-(CH 2) 2-、“亚丙基”指-(CH 2) 3-、“亚丁基”指-(CH 2) 4-等。
术语“烯基”指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的烷基，例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。烯基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“螺环烷基”指5至20元的单环之间共用一个碳原子(称螺原子)的多环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基，优选为单螺环烷基和双螺环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。螺环烷基的非限制性实例包括：
Figure PCTCN2018114798-appb-000019
术语“稠环烷基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团，其中一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基，优选为双环或三环，更优选为5元/5元或5元/6元双环烷基。稠环烷基的非限制性实例包括：
Figure PCTCN2018114798-appb-000020
术语“桥环烷基”指5至20元，任意两个环共用两个不直接连接的碳原子的全碳多环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基，优选为双环、三环或四环，更有选为双环或三环。桥环烷基的非限制性实例包括：
Figure PCTCN2018114798-appb-000021
所述环烷基环可以稠合于芳基、杂芳基或杂环烷基环上，其中与母体结构连接在一起的环为环烷基，非限制性实例包括茚满基、四氢萘基、苯并环庚烷基等。环烷基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基，优选为单螺杂环基和双螺杂环基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。螺杂环基的非限制性实例包括：
Figure PCTCN2018114798-appb-000022
术语“稠杂环基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基，优选为双环或三环，更优选为5元/5元或5元/6元双环稠杂环基。稠杂环基的非限制性实例包括：
Figure PCTCN2018114798-appb-000023
术语“桥杂环基”指5至14元，任意两个环共用两个不直接连接的原子的多环杂环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基，优选为双环、三环或四环，更有选为双环或三环。桥杂环基的非限制性实例包括：
Figure PCTCN2018114798-appb-000024
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环基，其非限制性实例包括：
Figure PCTCN2018114798-appb-000025
等。
杂环基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1～4个是杂原子；最优选包含3至8个环原子，其中1～3是杂原子；最优选包含3至6个环原子，其中1～2是杂原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基等，优选哌啶基、吡咯烷基、吡喃基、吗啉基或
Figure PCTCN2018114798-appb-000026
多环杂环基包括螺环、稠环和桥环的杂环基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基。更优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
Figure PCTCN2018114798-appb-000027
Figure PCTCN2018114798-appb-000028
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至10元，含1至3个杂原子；更优选为5元或6元，含1至2个杂原子；优选例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等，优选为咪唑基、四唑基、噻吩基、吡唑基或嘧啶基、噻唑基；更有选吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，其非限制性实例包括：
Figure PCTCN2018114798-appb-000029
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“卤代烷基”指被一个或多个卤素取代的烷基，其中烷基如上所定义。
术语“卤代烷氧基”指被一个或多个卤素取代的烷氧基，其中烷氧基如上所定义。
术语“羟烷基”指被羟基取代的烷基，其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH 2。
术语“氰基”指-CN。
术语“硝基”指-NO 2。
术语“氧代基”指＝O。
术语“羰基”指C＝O。
术语“羧基”指-C(O)OH。
术语“异氰酸基”指-NCO。
术语“肟基”指＝N-OH。
术语“羧酸酯基”指-C(O)O(烷基)或-C(O)O(环烷基)，其中烷基、环烷基如上所定义。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生的场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1～3个氢原子彼此独立地被相应数目的取代基取代。不言而喻，取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
除非有相反陈述，在说明书和权利要求书中使用的英文缩写具有下述含义。
Figure PCTCN2018114798-appb-000030
Figure PCTCN2018114798-appb-000031
具体实施方式
以下将结合具体实例详细地解释本发明，使得本专业技术人员更全面地理解本发明具体实例仅用于说明本发明的技术方案，并不以任何方式限定本发明。
化合物的结构是通过核磁共振(NMR)或质谱(MS)来确定的。NMR的测定是用Bruker AVANCE-400核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)、氘代氯仿(CDCl3)、氘代甲醇(CD3OD)，内标为四甲基硅烷(TMS)，化学位移是以10 -6(ppm)作为单位给出。
MS的测定用FINNIGAN LCQAd(ESI)质谱仪(生产商：Thermo,型号：Finnigan LCQ advantage MAX)。
HPLC的测定使用WATER e2695-2489高效液相色谱仪。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自BEPHARM等公司。
实施例1
第一步：2-乙基-6-碘苯甲酸
Figure PCTCN2018114798-appb-000032
将Ⅷa(100g，667mmol)溶于1000mL N,N-二甲基甲酰胺中，搅拌溶解，依次加入NIS(165g，733mmol)和Pd(OAc) 2(3g，13.4mmol)，氩气置换两次，升温至100℃，搅拌反应，薄层检测原料Ⅷa转化完全，停止反应。
后处理：反应液倒入2L水中，乙酸乙酯萃取3次，合并有机相，浓缩除去大部分乙酸乙酯后依次用饱和硫代硫酸钠溶液、饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，得到粗品184g，m/z[M-H] -＝275.1， 1H NMR(400MHz,CHLOROFORM-d)ppm:11.85(br.s.,1H),7.72(d,1H),7.28(d,1H),7.07-7.14(m,1H),2.78(q,2H),1.29(t,3H)，产物不经纯化直接进行下一步反应。
第二步：3,5-二溴-2-乙基-6-碘苯甲酸
Figure PCTCN2018114798-appb-000033
将Ⅶa(27.6g，83mmol)溶于138mL浓硫酸(5mL/g)中，降温至0-5℃，将N-溴代琥珀酰亚胺(19.6g，110mmol)溶于三氟乙酸，缓慢滴加上述的N-溴代琥珀酰亚胺的三氟乙酸溶液至反应液中，加毕，自然升至室温后反应一段时间后，后继续升40℃后，滴加N-溴代琥珀酰亚胺的三氟乙酸溶液(14.2g，80mmol)，检测Ⅶa<2％后停止反应。
后处理：反应液倒入4倍体积冰水中，固体析出，过滤，固体用乙酸乙酯溶解，无水硫酸钠干燥后，旋干得粗品，乙酸乙酯重结晶，真空干燥，得到29.5g类白色固体，产率：82％；纯度95.0％。m/z[M-H] -＝432.8
第三步：6-溴-5-乙基-2-(哌啶-1-基甲基)苯并呋喃-4-甲酸
Figure PCTCN2018114798-appb-000034
将Ⅵa(100g，230.4mmol)、碳酸铯(187.6g，576mmol)、碘化亚铜(13.16g，69.12mmol)、去离子水(16.6g，921.6mmol)溶于800mL DMSO中，加入Ⅴa(34.04g，276.5mmol)，氩气置换三次，升温至110℃，搅拌反应5小时，薄层跟踪至原料点Ⅵa消失，终止反应。
后处理：反应液趁热过滤，滤饼用少量DMSO淋洗，后将滤液缓慢倒入氯化钠溶液中，冰浴条件下用HCl溶液调节pH至5.5，有固体析出，继续搅拌后过滤真空烘干后异丙醇重结晶，得到标题产物48.8g(类白色固体)，纯度：97.3％。m/z[M，M+2]＝366,368
第四步：5-乙基-2-(哌啶-1-基甲基)-6-((四氢-2H-吡喃-4-基)氨基)苯并呋喃-4-甲酸
Figure PCTCN2018114798-appb-000035
将Ⅳa(200mg，0.546mmol)、DPE-Phos(双(2-二苯基膦苯基)醚)(47.1mg，0.087mmol)、Pd 2(dba) 3(10mg，0.011mmol)、t-BuONa(262.5mg，2.73mmol)和2mL甲苯加入到反应瓶中，加入四氢-2H-吡喃-4-胺(110.4mg，1.09mmol)，氩气置换三次，油浴加热至105-108℃，搅拌反应薄层跟踪至原料Ⅳa消失，停止反应。
后处理：反应液冷却至室温，倒入10mL水中，稀盐酸调节PH至7-8，分出水相，水相再用稀盐酸调节pH至6左右，接近等电点，二氯甲烷和甲醇混合溶剂萃取3次，合并有机相，无水硫酸钠干燥，过滤，滤液减压浓缩，柱层析，洗脱液(二氯甲烷∶甲醇＝20:1)，得到产品Ⅲa 120mg(棕色固体)。m/z[M+H] +＝387.4
第五步：5-乙基-6-(乙基(四氢-2H-吡喃-4-基)氨基)-2-(哌啶-1-基甲基)苯并呋喃-4-羧酸
Figure PCTCN2018114798-appb-000036
将原料Ⅲa(120mg，0.31mmol)置于25mL三颈瓶中，加入3mL DCM，冰浴下加入乙醛(69mg，1.55mmol)和乙酸(94mg，1.55mmol)，搅拌反应0.5小时，冰浴下，分次加入三乙酰氧基硼氢化钠(198mg，0.93mmol)，升温至室温，搅拌反应反应至薄层跟踪至原料点Ⅲa消失，终止反应。
后处理：反应液中加入50mL饱和氯化钠溶液，搅拌0.5小时。分液，有机相用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，减压浓缩，得到产品94mg。m/z[M+H] +＝415.5
1H NMR(400MHz,DMSO-d6)ppm 7.55(s,1H)6.76(s,1H)3.82(d,2H)3.65(s,2H)3.22(t,2H)3.05(q,4H)2.95(t,1H)2.46(br.s.,4H)1.66(br.s.,2H)1.44-1.56(m,6H)1.37(br.s.,2H)1.03-1.14(m,3H)0.81(t,3H)
第六步：N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-乙基-6-(乙基(四氢-2H-吡喃-4-基)氨基)-2-(哌啶-1-基甲基)苯并呋喃-4-甲酰胺
Figure PCTCN2018114798-appb-000037
25mL三口瓶中，将原料Ⅱa(50mg，0.12mmol)，1-乙基-3(3-二甲基丙胺)碳二亚胺(34.5mg，0.18mmol)，1-羟基苯并三唑(23.67mg，0.18mmol),和N,N-二异丙基乙基胺(77.89mg，0.6mmol)混合，溶于3mL N,N-二甲基甲酰胺中，搅拌均匀；加入原料3-(氨基甲基)-4,6-二甲基吡啶-2(1H)-酮盐酸盐(24.9mg，0.13mmol)，室温搅拌反应至薄层跟踪至原料点Ⅱa消失，终止反应。向反应液中加入过量水，用二氯甲烷和甲醇的混合溶剂萃取，合并有机相，水洗，饱和氯化钠溶液洗，无水硫酸钠干燥，过滤，减压浓缩，用硅胶柱色谱法以二氯甲烷-甲醇洗脱剂体系纯化所得残留物，得30.1mg白色固体，收率，47.0％。
m/z[M+H] +＝549.6
1H NMR(400MHz,DMSO-d6)ppm 11.51(s,1H)8.17(t,1H)7.39(s,1H)6.47(s,1H)5.86(s,1H)4.32(d,2H)3.83(d,2H)3.53(s,2H)3.21(t,2H)3.04(d,2H)2.94(br.s.,1H)2.79(d,2H)2.38(br.s.,4H)2.23(s,3H)2.08-2.14(m,3H)1.65(d,2H)1.44-1.56(m,6H)1.36(d,2H)1.02(t,3H)0.81(t,3H).

Claims (26)

  1. 一种式Ⅳ所示的苯并呋喃衍生物的制备方法，其特征在于式Ⅵ所示化合物与式Ⅴ所示化合物发生反应得到式Ⅳ所示化合物，
    Figure PCTCN2018114798-appb-100001
    其中，X、Y各自独立的选自氟、氯、溴、碘、-OS(O) 2烷基、和-OS(O) 2芳基，优选碘、溴；
    R 1、R 2、R 3各自相同或不同，且各自独立选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、羟基、氰基、环烷基、杂环基、芳基、杂芳基、-OR 4、-C(O)R 4、-C(O)OR 4、-OS(O) 2烷基、和-OS(O) 2芳基、-S(O) mR 4、-S(O) mNR 5R 6和-(CH 2)xR a，其中所述的烷基、卤代烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
    E选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、-OR4、-C(O)R 4、-C(O)OR 4、-OS(O) 2烷基、和-OS(O) 2芳基、-S(O)mR 4、-S(O)mNR 5R 6和-(CH2)xR a，其中所述的烷基、卤代烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
    R a选自卤素、环烷基、杂环基和-NR 5R 6，其中所述的环烷基和杂环基各自独立地任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
    R 4选自氢原子、烷基、卤代烷基、烷氧基、羟烷基、羟基、氨基、环烷基、杂环基、芳基和杂芳基；
    R 5和R 6相同或不同，且各自独立地选自氢原子、烷基、烷氧基、羟烷基、羟基、氨基、羧酸酯基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、氨基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
    M选自羧基、氢、硅烷基，优选氢；
    m为0、1或2；
    x为0、1、2或3。
  2. 根据权利要求1所述的制备方法，其特征在于式Ⅵ所示化合物与式Ⅴ所示化合物 在至少一种金属催化剂和/或至少一种碱性物质的作用下反应。
  3. 根据权利要求2所述的制备方法，其特征在于所述金属催化剂选自金属钯催化剂、金属锌催化剂、金属铜催化剂、金属镍催化剂，优选金属铜催化剂，更优选一价金属铜催化剂。
  4. 根据权利要求2-3任一项所述的制备方法，其特征在于所述碱性物质选自KHCO 3、NaHCO 3、Na 2CO 3,Ba(OH) 2、K 3PO 4、Cs 2CO 3、K 2CO 3、KF、CsF、KCN、NaCN、NaOH、KOH、Et 3N、DIPEA、DABCO、NaOMe、NaOEt、 tBuOK、 tBuONa、NaH、DBU、TMG、LHMDS、NaHMDS、n-BuLi、叔戊醇钠,二乙基胺、二环己基胺，优选 tBuOK、 tBuONa。
  5. 根据权利要求1-4任一项所述的制备方法，其特征在于反应溶剂选自二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、异丙醇、丙醇、乙醇、甲醇、水中的一种或多种。
  6. 根据权利要求1-5任一项所述的制备方法，其特征在于反应在惰性气体保护下进行，所述惰性气体选自氮气、氩气、氦气，优选氩气。
  7. 一种权利要求1-6任一项所述的制备方法，该方法包含式Ⅵa所示化合物与式Ⅴa所示化合物发生反应得到Ⅳa所示化合物的步骤，
    Figure PCTCN2018114798-appb-100002
  8. 一种式Ⅵa所示化合物的制备方法，其特征在于包含式Ⅶa所示化合物在溴代试剂和至少一种酸的作用下生产Ⅵa所示化合物的步骤，
    Figure PCTCN2018114798-appb-100003
  9. 根据权利要求8所述的制备方法，其特征在于所述溴代试剂选自HBr、Br 2、NBS、DBDMH、HOBr、AcOBr、CF 3COOBr、NH 4Br、TBBDA、PBBS、三溴异氰基脲，优选NBS、DBDMH。
  10. 根据权利要求8-9任一项所述的制备方法，其特征在于所述酸选自AlCl 3、SbCl 5、FeCl 3、FeBr 3、SnCl 4、TiCl 4、ZnCl 2、BF 3、醋酸、硫酸、盐酸、三氟乙酸，优选硫酸、三氟乙酸。
  11. 根据权利要求7所述的式Ⅳa所示化合物的制备方法，其特征在于还包含权利要求8-10任一项所述的制备式Ⅵa所示化合物的方法。
  12. 一种式Ⅶa所示的化合物的制备方法，其特征在于式Ⅷa所示化合物在一种或多 种选自Pd 2(dba) 3、Pd(dba) 2、Pd(OAc) 2、Pd(tfa) 2、Pd(Piv) 2、Pd(OTf) 2、Pd(PPh 3) 4、PdCl 2、Pd(PPh 3) 2Cl 2、Pd(dppf)Cl 2的钯催化剂和一种或多种选自NIS、I(Py) 2BF 4、IOAC、KI、KIO 3、NaI、IBr的碘代试剂作用下得到式Ⅶa所示化合物，所述钯催化剂优选Pd(OAc) 2，所述碘代试剂优选NIS，
    Figure PCTCN2018114798-appb-100004
  13. 根据权利要求8-10任一项所述的制备式Ⅵa所示的化合物的方法，其特征在于还包括权利要求12的制备式Ⅶa所示的化合物的方法。
  14. 一种式Ⅲa所示化合的制备方法，其特征在于式Ⅳa所示化合物与四氢-2H-吡喃-4-胺反应得式Ⅲa所示化合物，
    Figure PCTCN2018114798-appb-100005
  15. 根据权利要求14所示的式Ⅲa所示化合的制备方法，其特征在于包含权利要求7、11任一项所示的制备式Ⅳa所示化合物的方法。
  16. 根据权利要求14-15任一项所述的式Ⅲa所示化合的制备方法，其特征在于进一步包含权利要求6、13任一项所述的制备式Ⅵa所示化合物的方法。
  17. 一种式Ⅱa所示的化合物的制备方法，其特征在于式Ⅲa所示化合物发生N-乙基化，得到Ⅱa所示化合物，
    Figure PCTCN2018114798-appb-100006
  18. 根据权利要求17所述的式Ⅱa所示化合物的制备方法，其特征在于进一步包含权利要求14-16任一项所述的式Ⅲa所示化合物的制备方法。
  19. 一种式Ⅰa所示的化合物的制备方法，其特征在于包含式Ⅱa所示化合物与3-(氨基甲基)-4,6-二甲基吡啶-2(1H)-酮盐酸盐反应制备得到Ⅰa的步骤，还包含权利要求17-18任一项所述的制备式Ⅱa所示化合物的方法，
    Figure PCTCN2018114798-appb-100007
  20. 根据权利要求19所述的制备式Ⅰa所示的化合物的方法，其特征在于进一步包含权利要求14-16任一项所述的制备式Ⅲa所示化合物的方法。
  21. 根据权利要求19-20任一项所述的制备式Ⅰa所示的化合物的方法，其特征在于进一步包含权利要求7、11任一项所述的制备式Ⅳa所示化合物的方法。
  22. 一种式Ⅳ所示的化合物：
    Figure PCTCN2018114798-appb-100008
    其中E、R 1、R 2、R 3如权利要求1中所定义。
  23. 一种式Ⅵ所示的化合物：
    Figure PCTCN2018114798-appb-100009
    其中X、Y、R 1、R 2、R 3如权利要求1所定义。
  24. 一种式Ⅵa所示的化合物：
    Figure PCTCN2018114798-appb-100010
  25. 一种式Ⅳa所示的化合物：
    Figure PCTCN2018114798-appb-100011
  26. 一种式Ⅲa所示的化合物：
    Figure PCTCN2018114798-appb-100012
PCT/CN2018/114798 2017-11-10 2018-11-09 一种苯并呋喃衍生物的制备方法 WO2019091450A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP18875981.5A EP3708567A4 (en) 2017-11-10 2018-11-09 PROCESS FOR THE PREPARATION OF A BENZOFURANE DERIVATIVE
CN201880059239.2A CN111094279B (zh) 2017-11-10 2018-11-09 一种苯并呋喃衍生物的制备方法
MX2020004869A MX2020004869A (es) 2017-11-10 2018-11-09 Metodo para preparar derivado de benzofurano.
JP2020525952A JP7295105B6 (ja) 2017-11-10 2018-11-09 ベンゾフラン誘導体の製造方法
US16/762,795 US11390614B2 (en) 2017-11-10 2018-11-09 Method for preparing benzofuran derivative
AU2018363467A AU2018363467B2 (en) 2017-11-10 2018-11-09 Method for preparing benzofuran derivative
RU2020118301A RU2777624C2 (ru) 2017-11-10 2018-11-09 Способ получения производного бензофурана
JP2023094525A JP7526856B2 (ja) 2017-11-10 2023-06-08 ベンゾフラン誘導体の製造方法
AU2023278061A AU2023278061A1 (en) 2017-11-10 2023-12-07 Method for preparing benzofuran derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711104888.3 2017-11-10
CN201711104888 2017-11-10

Publications (1)

Publication Number Publication Date
WO2019091450A1 true WO2019091450A1 (zh) 2019-05-16

Family

ID=66438760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/114798 WO2019091450A1 (zh) 2017-11-10 2018-11-09 一种苯并呋喃衍生物的制备方法

Country Status (8)

Country Link
US (1) US11390614B2 (zh)
EP (1) EP3708567A4 (zh)
JP (2) JP7295105B6 (zh)
CN (1) CN111094279B (zh)
AU (2) AU2018363467B2 (zh)
MX (1) MX2020004869A (zh)
TW (1) TWI717656B (zh)
WO (1) WO2019091450A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
WO2023061467A1 (zh) 2021-10-15 2023-04-20 江苏恒瑞医药股份有限公司 一种苯并呋喃衍生物的制备方法
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114456156A (zh) * 2020-11-09 2022-05-10 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的纯化方法
CN113861002B (zh) * 2021-11-02 2024-04-26 琼台师范学院 一种无金属催化体系催化氧化芳香醇类制备芳香酮类化合物的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236625A (en) * 1963-07-18 1966-02-22 Tenneco Chem Method of inhibiting plant growth
CN1426388A (zh) * 2000-04-28 2003-06-25 日本农药株式会社 生产2－卤代苯甲酸的方法
CN101434582A (zh) * 2008-11-28 2009-05-20 华东理工大学 苯甲酸(苯并三唑基)苯酯类化合物
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2012142513A1 (en) 2011-04-13 2012-10-18 Epizyme, Inc. Substituted benzene compounds
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2015141616A1 (ja) 2014-03-17 2015-09-24 第一三共株式会社 １，３－ベンゾジオキソール誘導体
WO2017084494A1 (zh) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3233678B2 (ja) 1991-06-27 2001-11-26 日本化学工業株式会社 ｏ−アルコキシ安息香酸の製造方法
DK0923568T5 (da) 1996-08-19 2003-11-03 Altana Pharma Ag Hidtil ukendte benzofuran-4-carboxamider
GB0003257D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
WO2002010156A1 (en) 2000-07-29 2002-02-07 Arpida Ag Benzofuran derivatives and their use as antibacterial agents
FR2923826A1 (fr) 2007-11-21 2009-05-22 Ppg Sipsy Soc Par Actions Simp Procede de synthese de l'acide 4-benzofurane carboxylique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236625A (en) * 1963-07-18 1966-02-22 Tenneco Chem Method of inhibiting plant growth
CN1426388A (zh) * 2000-04-28 2003-06-25 日本农药株式会社 生产2－卤代苯甲酸的方法
CN101434582A (zh) * 2008-11-28 2009-05-20 华东理工大学 苯甲酸(苯并三唑基)苯酯类化合物
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2012142513A1 (en) 2011-04-13 2012-10-18 Epizyme, Inc. Substituted benzene compounds
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2015141616A1 (ja) 2014-03-17 2015-09-24 第一三共株式会社 １，３－ベンゾジオキソール誘導体
WO2017084494A1 (zh) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
CN113767096A (zh) * 2019-05-10 2021-12-07 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
CN113767096B (zh) * 2019-05-10 2022-11-22 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
WO2023061467A1 (zh) 2021-10-15 2023-04-20 江苏恒瑞医药股份有限公司 一种苯并呋喃衍生物的制备方法
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders

Also Published As

Publication number Publication date
JP7295105B6 (ja) 2023-07-24
JP7295105B2 (ja) 2023-06-20
US11390614B2 (en) 2022-07-19
US20210188822A1 (en) 2021-06-24
MX2020004869A (es) 2020-08-06
AU2018363467B2 (en) 2023-09-07
EP3708567A1 (en) 2020-09-16
JP2023123543A (ja) 2023-09-05
CN111094279B (zh) 2023-06-16
TWI717656B (zh) 2021-02-01
EP3708567A4 (en) 2021-07-07
RU2020118301A3 (zh) 2022-01-27
AU2023278061A1 (en) 2024-01-04
RU2020118301A (ru) 2021-12-10
AU2018363467A1 (en) 2020-06-04
CN111094279A (zh) 2020-05-01
TW201918469A (zh) 2019-05-16
JP7526856B2 (ja) 2024-08-01
JP2021502376A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
TWI717656B (zh) 苯並呋喃衍生物的製備方法
CN113767096B (zh) 一种6-取代氨基苯并呋喃化合物的制备方法
JP7131837B2 (ja) Ｃｓｆ－１ｒ阻害活性を有するアザアリール誘導体、その製造方法および応用
WO2014125408A2 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
AU2021208113B2 (en) Azabicyclic substituted oxaspiro derivative, preparation method therefor and medical use thereof
CA2783340C (en) Inhibitors of akt activity
JP2022552132A (ja) 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
CA3069602C (en) Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof
WO2019196915A1 (zh) 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体
WO2023072143A1 (zh) 一种喜树碱类衍生物中间体、其制备方法和用途
JP2022531936A (ja) イミダゾ［１，２－ａ］ピリミジンの位置選択的合成
RU2777624C2 (ru) Способ получения производного бензофурана
JP2022513215A (ja) Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途
WO2019076316A1 (zh) 一种酪氨酸激酶抑制剂及其中间体的制备方法
WO2024251211A1 (en) Compositions, methods, and systems for modulating splicing of msh3
WO2014125410A1 (en) N-substituted heterocyclic derivatives as kinase inhibitors
RU2777675C2 (ru) Способ получения ингибитора тирозинкиназы и его промежуточного соединения
JP2024537339A (ja) ベンゾフラン誘導体の調製方法
WO2022166468A1 (zh) Bruton&#39;s酪氨酸激酶抑制剂及其应用
CN116514807A (zh) 一种萘啶酮类衍生物及其制备方法
AU2014253232A1 (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
KR20170044166A (ko) 3-페닐/헤테로아릴-6-페녹시-8-알킬아미노-이미다조[1,2-ｂ]피리다진 유도체의 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18875981

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020525952

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018363467

Country of ref document: AU

Date of ref document: 20181109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018875981

Country of ref document: EP

Effective date: 20200610